Truncated ERG proteins affect the aggressiveness of prostate cancer

Medical Hypotheses

Volumn 80, Issue 4, 2013, Pages 490-493

  Wu, Fei ^a   Ding, Sentai ^a   Lu, Jiaju ^a  

^a SHANDONG PROVINCIAL HOSPITAL AFFILIATED TO SHANDONG UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

ONCOPROTEIN; TMPRSS2 PROTEIN; TRANSCRIPTION FACTOR ERG; UNCLASSIFIED DRUG;

AMINO TERMINAL SEQUENCE; ARTICLE; BINDING SITE; CANCER GROWTH; CANCER INVASION; CARBOXY TERMINAL SEQUENCE; CARCINOGENESIS; DNA SEQUENCE; FUSION GENE; GENE FUSION; GENE OVEREXPRESSION; GENETIC ASSOCIATION; HUMAN; MOLECULAR MECHANICS; ONCOGENE; PROSTATE CANCER; PROTEIN BINDING; PROTEIN DOMAIN; PROTEIN STRUCTURE; TRANSCRIPTION INITIATION;

GENE FUSION; GENETIC PREDISPOSITION TO DISEASE; HUMANS; MALE; ONCOGENE PROTEINS, FUSION; PROSTATIC NEOPLASMS; PROTO-ONCOGENE PROTEINS C-ETS; TRANS-ACTIVATORS;

EID: 84875395035     PISSN: 03069877     EISSN: 15322777     Source Type: Journal    
DOI: 10.1016/j.mehy.2012.12.012     Document Type: Article

References (47)

1. Jemal A., Bray F., Center M.M., et al. Global cancer statistics. CA Cancer J Clin 2011, 61(2):69-90.
2. Schroder F.H., Hugosson J., Carlsson S., et al. Screening for Prostate Cancer Decreases the Risk of Developing Metastatic Disease: Findings from the European Randomized Study of Screening for Prostate Cancer (ERSPC). Eur Urol 2012, 62(5):745-752.
3. Schurko B., Oh W.K. Docetaxel chemotherapy remains the standard of care in castration-resistant prostate cancer. Nat Clin Pract Oncol 2008, 5(9):506-507.
4. Kantoff P.W., Higano C.S., Shore N.D., et al. Sipuleucel-T immunotherapy for castration-resistant prostate cancer. N Engl J Med 2010, 363(5):411-422.
5. Mitelman F., Johansson B., Mertens F. The impact of translocations and gene fusions on cancer causation. Nat Rev Cancer 2007, 7(4):233-245.
6. Tomlins S.A., Rhodes D.R., Perner S., et al. Recurrent fusion of TMPRSS2 and ETS transcription factor genes in prostate cancer. Science 2005, 310(5748):644-648.
7. Huang W., Waknitz M. ETS gene fusions and prostate cancer. Am J Transl Res 2009, 1(4):341-351.
8. Kumar-Sinha C., Tomlins S.A., Chinnaiyan A.M. Recurrent gene fusions in prostate cancer. Nat Rev Cancer 2008, 8(7):497-511.
9. Vaarala M.H., Porvari K., Kyllonen A., et al. The TMPRSS2 gene encoding transmembrane serine protease is overexpressed in a majority of prostate cancer patients: detection of mutated TMPRSS2 form in a case of aggressive disease. Int J Cancer 2001, 94(5):705-710.
10. Oikawa T., Yamada T. Molecular biology of the ETS family of transcription factors. Gene 2003, 303:11-34.
11. Tsuzuki S., Taguchi O., Seto M. Promotion and maintenance of leukemia by ERG. Blood 2011, 117(14):3858-3868.
12. Martens J.H. Acute myeloid leukemia: a central role for the ETS factor ERG. Int J Biochem Cell Biol 2011, 43(10):1413-1416.
13. Gupta S., Iljin K., Sara H., et al. FZD4 as a mediator of ERG oncogene-induced WNT signaling and epithelial-to-mesenchymal transition in human prostate cancer cells. Cancer Res 2010, 70(17):6735-6745.
14. Mohamed A.A., Tan S.H., Sun C., et al. ERG oncogene modulates prostaglandin signaling in prostate cancer cells. Cancer Biol Ther 2011, 11(4):410-417.
15. Flajollet S., Tian T.V., Flourens A., et al. Abnormal expression of the ERG transcription factor in prostate cancer cells activates osteopontin. Mol Cancer Res 2011, 9(7):914-924.
16. Rickman D.S., Chen Y.B., Banerjee S., et al. ERG cooperates with androgen receptor in regulating trefoil factor 3 in prostate cancer disease progression. Neoplasia 2010, 12(12):1031-1040.
17. Taoudi S., Bee T., Hilton A., et al. ERG dependence distinguishes developmental control of hematopoietic stem cell maintenance from hematopoietic specification. Genes Dev 2011, 25(3):251-262.
18. Hessels D., Smit F.P., Verhaegh G.W., et al. Detection of TMPRSS2-ERG fusion transcripts and prostate cancer antigen 3 in urinary sediments may improve diagnosis of prostate cancer. Clin Cancer Res 2007, 13(17):5103-5108.
19. Tomlins S.A., Bjartell A., Chinnaiyan A.M., et al. ETS gene fusions in prostate cancer: from discovery to daily clinical practice. Eur Urol 2009, 56(2):275-286.
20. Demichelis F., Fall K., Perner S., et al. TMPRSS2: ERG gene fusion associated with lethal prostate cancer in a watchful waiting cohort. Oncogene 2007, 26(31):4596-4599.
21. Attard G., Clark J., Ambroisine L., et al. Duplication of the fusion of TMPRSS2 to ERG sequences identifies fatal human prostate cancer. Oncogene 2008, 27(3):253-263.
22. FitzGerald L.M., Agalliu I., Johnson K., et al. Association of TMPRSS2-ERG gene fusion with clinical characteristics and outcomes: results from a population-based study of prostate cancer. BMC Cancer 2008, 8:230.
23. Rostad K., Hellwinkel O.J., Haukaas S.A., et al. TMPRSS2: ERG fusion transcripts in urine from prostate cancer patients correlate with a less favorable prognosis. APMIS 2009, 117(8):575-582.
24. Lapointe J., Kim Y.H., Miller M.A., et al. A variant TMPRSS2 isoform and ERG fusion product in prostate cancer with implications for molecular diagnosis. Mod Pathol 2007, 20(4):467-473.
25. Minner S., Enodien M., Sirma H., et al. ERG status is unrelated to PSA recurrence in radically operated prostate cancer in the absence of antihormonal therapy. Clin Cancer Res 2011, 17(18):5878-5888.
26. Darnel A.D., Lafargue C.J., Vollmer R.T., et al. TMPRSS2-ERG fusion is frequently observed in Gleason pattern 3 prostate cancer in a Canadian cohort. Cancer Biol Ther 2009, 8(2):125-130.
27. Saramaki O.R., Harjula A.E., Martikainen P.M., et al. TMPRSS2: ERG fusion identifies a subgroup of prostate cancers with a favorable prognosis. Clin Cancer Res 2008, 14(11):3395-3400.
28. Gopalan A., Leversha M.A., Satagopan J.M., et al. TMPRSS2-ERG gene fusion is not associated with outcome in patients treated by prostatectomy. Cancer Res 2009, 69(4):1400-1406.
29. Fine S.W., Gopalan A., Leversha M.A., et al. TMPRSS2-ERG gene fusion is associated with low Gleason scores and not with high-grade morphological features. Mod Pathol 2010, 23(10):1325-1333.
30. Graves B.J., Petersen J.M. Specificity within the ETS family of transcription factors. Adv Cancer Res 1998, 75:1-55.
31. Laudet V., Hanni C., Stehelin D., et al. Molecular phylogeny of the ETS gene family. Oncogene 1999, 18(6):1351-1359.
32. Kim C.A., Phillips M.L., Kim W., et al. Polymerization of the SAM domain of TEL in leukemogenesis and transcriptional repression. EMBO J 2001, 20(15):4173-4182.
33. Rao V.N., Ohno T., Prasad D.D., et al. Analysis of the DNA-binding and transcriptional activation functions of human Fli-1 protein. Oncogene 1993, 8(8):2167-2173.
34. Paoloni-Giacobino A., Chen H., Peitsch M.C., et al. Cloning of the TMPRSS2 gene, which encodes a novel serine protease with transmembrane, LDLRA, and SRCR domains and maps to 21q22.3. Genomics 1997, 44(3):309-320.
35. Perner S., Demichelis F., Beroukhim R., et al. TMPRSS2: ERG fusion-associated deletions provide insight into the heterogeneity of prostate cancer. Cancer Res 2006, 66(17):8337-8341.
36. Mertz K.D., Setlur S.R., Dhanasekaran S.M., et al. Molecular characterization of TMPRSS2-ERG gene fusion in the NCI-H660 prostate cancer cell line: a new perspective for an old model. Neoplasia 2007, 9(3):200-206.
37. Iljin K., Wolf M., Edgren H., et al. TMPRSS2 fusions with oncogenic ETS factors in prostate cancer involve unbalanced genomic rearrangements and are associated with HDAC1 and epigenetic reprogramming. Cancer Res 2006, 66(21):10242-10246.
38. Soller M.J., Isaksson M., Elfving P., et al. Confirmation of the high frequency of the TMPRSS2/ERG fusion gene in prostate cancer. Genes Chromosomes Cancer 2006, 45(7):717-719.
39. Clark J., Merson S., Jhavar S., et al. Diversity of TMPRSS2-ERG fusion transcripts in the human prostate. Oncogene 2007, 26(18):2667-2673.
40. Hu Y., Dobi A., Sreenath T., et al. Delineation of TMPRSS2-ERG splice variants in prostate cancer. Clin Cancer Res 2008, 14(15):4719-4725.
41. Tu J.J., Rohan S., Kao J., et al. Gene fusions between TMPRSS2 and ETS family genes in prostate cancer: frequency and transcript variant analysis by RT-PCR and FISH on paraffin-embedded tissues. Mod Pathol 2007, 20(9):921-928.
42. Lucas J.M., True L., Hawley S., et al. The androgen-regulated type II serine protease TMPRSS2 is differentially expressed and mislocalized in prostate adenocarcinoma. J Pathol 2008, 215(2):118-125.
43. Tomlins S.A., Laxman B., Varambally S., et al. Role of the TMPRSS2-ERG gene fusion in prostate cancer. Neoplasia 2008, 10(2):177-188.
44. Hollenhorst P.C., Chandler K.J., Poulsen R.L., et al. DNA specificity determinants associate with distinct transcription factor functions. PLoS Genet 2009, 5(12):e1000778.
45. Clark J.P., Cooper C.S. ETS gene fusions in prostate cancer. Nat Rev Urol 2009, 6(8):429-439.
46. Sreenath T.L., Dobi A., Petrovics G., et al. Oncogenic activation of ERG: a predominant mechanism in prostate cancer. J Carcinog 2011, 10:37.
47. Chen Y., Sawyers C.L. Coordinate transcriptional regulation by ERG and androgen receptor in fusion-positive prostate cancers. Cancer Cell 2010, 17(5):415-416.